RecruitingPhase 4NCT05347069
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
Sponsor
Takeshi Morimoto
Enrollment
2,890 participants
Start Date
Jun 14, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.
Eligibility
Min Age: 20 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Aspirin and a drug called No aspirin for people with coronary artery disease, ischemic heart disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAspirin
Aspirin 100 mg/day
DRUGNo aspirin
No aspirin administered
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05347069
Related Trials
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
NCT072582902 locations
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT0677963023 locations
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT0704519415 locations
CPB and Aortic Cross-Clamp Durations and ICU Length of Stay After CABG Retrospective Observational Cohort Study
NCT077119511 location
Digital Long-term Follow-up of Patients With Coronary Artery Disease: a Randomized Controlled Trial
NCT077203492 locations